US FDA panel review set for Acusphere's imaging agent
This article was originally published in Scrip
The US FDA's cardiovascular and renal drugs advisory panel will meet on December 10th to discuss Acusphere's cardiovascular ultrasound imaging agent Imagify (perflubutane polymer microspheres). The proposed use is for patients with stable chest pain being evaluated for inducible ischaemia for the detection of coronary artery disease based on assessment of myocardial perfusion and wall motion. Imagify is the first ultrasound imaging agent designed to assess blood flow in the heart and the first to demonstrate, in large clinical trials, clinically equivalent accuracy to nuclear stress testing, the current standard for assessing myocardial perfusion, Acusphere said. The company said its lead product candidate would present a lower cost, speedier and non-radioactive option to nuclear stress testing .The NDA is undergoing a standard review, and the user fee date is February 28th.
You may also be interested in...
Experience and data from the study, which will use the same vector platform to deliver different transgenes for different diseases, could feed into the US FDA’s efforts to establish a public-private partnership to enable manufacturing of gene therapies for ultra-rare diseases.
A protocol amendment is not needed to pause enrollment to decrease potential exposure to COVID-19, and virtual visits can be immediately implemented to ensure safety; experts say pandemic is forcing a rethinking in how companies carry out trials and in how regulators ensure patient safety and trial integrity.
Agency is working with manufacturers, including Takeda and Emergent BioSolutions, to accelerate development of hyperimmune globulin products, with an eye toward starting clinical testing in several months; new FDA guidelines on convalescent plasma collection for single-patient emergency IND use are helpful in understanding agency expectations around source plasma collection for manufactured products as well, Emergent SVP Laura Saward says.